Cardiovascular benefits of GLP-1 agonists in type 2 diabetes: a comparative review
John Petrie
Clinical Science, 2018
View PDFchevron_right
GLP-1R as a Target for the Treatment of Diabetic Retinopathy: Friend or Foe?
Cristina Flores Hernández
Diabetes, 2017
View PDFchevron_right
Glucagon-Like Peptide 1 Receptor Agonists and Risk of Diabetic Retinopathy Complications: Cohort Study in Nationwide Registers From Two Countries
Soffia Gudbjörnsdottir
Diabetes Care
View PDFchevron_right
Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Incident Diabetic Retinopathy
Hui Yin
Diabetes care, 2018
View PDFchevron_right
GLP-1 receptor agonists, carotid atherosclerosis and retinopathy
Dragana Nikolic
Expert opinion on pharmacotherapy, 2017
View PDFchevron_right
Cardiovascular and Renal Effectiveness of GLP-1 Receptor Agonists vs. Other Glucose-Lowering Drugs in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Real-World Studies
Francesco Giorgino
Metabolites
View PDFchevron_right
Glucagon-like Peptide 1 Receptor Agonists, Diabetic Retinopathy and Angiogenesis: The AngioSafe Type 2 Diabetes Study
Philippe Mailly
The Journal of Clinical Endocrinology & Metabolism, 2019
View PDFchevron_right
Efficacy and safety of glucagon-like peptide-1 agonists on macrovascular and microvascular events in type 2 diabetes mellitus: A meta-analysis
Caterina Marciano
Nutrition, Metabolism and Cardiovascular Diseases, 2017
View PDFchevron_right
HbA1c Change and Diabetic Retinopathy During GLP-1 Receptor Agonist Cardiovascular Outcome Trials: A Meta-analysis and Meta-regression
Hertzel Gerstein
Diabetes Care, 2020
View PDFchevron_right
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Hertzel Gerstein
The Lancet Diabetes & Endocrinology, 2019
View PDFchevron_right
Cardiovascular safety of the GLP-1 receptor agonist taspoglutide in people with type 2 diabetes: An individual participant data meta-analysis of randomized controlled trials
John Petrie
Diabetes, Obesity and Metabolism, 2015
View PDFchevron_right
SGLT2 Inhibitors, GLP-1 Agonists, and DPP-4 Inhibitors in Diabetes and Microvascular Complications: A Review
Sami Azar
International Journal of Endocrinology
View PDFchevron_right
Oral GLP-1 analogue: perspectives and impact on atherosclerosis in type 2 diabetic patients
Denise Franco
Cardiovascular Diabetology, 2021
View PDFchevron_right
Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials
Niccolo' Marchionni
European Journal of Endocrinology, 2009
View PDFchevron_right
Indirect comparison of glucagon like peptide-1 receptor agonists regarding cardiovascular safety and mortality in patients with type 2 diabetes mellitus: network meta-analysis
Omar Almohammed
Cardiovascular Diabetology
View PDFchevron_right
Effect of the glucagon-like peptide-1 analogue liraglutide on coronary microvascular function in patients with type 2 diabetes - a randomized, single-blinded, cross-over pilot study
Josef Fontana
Cardiovascular diabetology, 2015
View PDFchevron_right
Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with Type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials
Caterina Marciano
European Heart Journal, 2020
View PDFchevron_right
Glucagon-like peptide 1 receptor agonist (GLP-1 RA): long-term effect on kidney function in patients with type 2 diabetes
Jens Goetze, Frederik Persson
Journal of diabetes and its complications, 2015
View PDFchevron_right
Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control
Vasilios Athyros
Diabetes, Obesity and Metabolism, 2011
View PDFchevron_right
Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Co-Transporter 2 Inhibitors for Prevention of MajorAdverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials
Remo Furtado
Circulation
View PDFchevron_right
The cardiovascular and renal effects of glucagon-like peptide 1 receptor agonists in patients with advanced diabetic kidney disease
Ning-I Yang
View PDFchevron_right
Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Events: A Meta-Analysis of Randomized Clinical Trials
Francesco Cremasco
Experimental Diabetes Research, 2011
View PDFchevron_right
Glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes:real-world evidence from a Mediterranean area
Gabriela Stefanescu
Current Medical Research and Opinion, 2019
View PDFchevron_right
GLP-1 receptor agonists and cardiovascular risk in routine clinical practice
Guntram Schernthaner
The Lancet Diabetes & Endocrinology, 2019
View PDFchevron_right
GLP 1 and Macrovascular Complications
Sami Azar
Journal of diabetes & metabolism, 2011
View PDFchevron_right
Locally delivered GLP-1 analogues liraglutide and exenatide enhance microvascular perfusion in individuals with and without type 2 diabetes
Myo Zaw Aung
Diabetologia, 2019
View PDFchevron_right
Metabolic and cardiovascular benefits of GLP‑1 agonists, besides the hypoglycemic effect (Review)
Carmen Pantis
Experimental and Therapeutic Medicine, 2020
View PDFchevron_right
A comparative safety review between GLP-1 receptor agonists and SGLT2 inhibitors for diabetes treatment
mariella baldassarre
Expert Opinion on Drug Safety, 2018
View PDFchevron_right
Future perspectives on glucagon-like peptide-1, diabetes and cardiovascular risk
Carlo Rotella
Nutrition, Metabolism and Cardiovascular Diseases, 2008
View PDFchevron_right
Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis
Ailsa Snaith
BMC Endocrine Disorders, 2010
View PDFchevron_right
Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonists for the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials
Despoina Vasilakou
Diabetes, Obesity and Metabolism, 2015
View PDFchevron_right
Characteristics predicting the efficacy of SGLT-2 inhibitors versus GLP-1 receptor agonists on major adverse cardiovascular events in type 2 diabetes mellitus: a meta-analysis study
Johannes W Dietrich
Cardiovascular Diabetology, 2023
View PDFchevron_right
Current Issues in GLP-1 Receptor Agonist Therapy for Type 2 Diabetes
Zachary Bloomgarden, Carol Wysham
Endocrine Practice, 2012
View PDFchevron_right
Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: Differences and similarities
Thazha Prakash
European Journal of Internal Medicine, 2014
View PDFchevron_right
GLP-1 receptor agonists in diabetic kidney disease: from the patient-side to the bench-side
Brad Dieter
American Journal of Physiology-Renal Physiology, 2018
View PDFchevron_right